Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jung Ho | - |
dc.contributor.author | Shin, Byung Cheol | - |
dc.contributor.author | Park, Won Sang | - |
dc.contributor.author | Lee, Jaehwi | - |
dc.contributor.author | Kuh, Hyo-Jeong | - |
dc.date.available | 2019-03-08T07:36:31Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 1349-7006 | - |
dc.identifier.issn | 1349-7006 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3552 | - |
dc.description.abstract | We investigated the combinatorial effects of pentoxifylline (PTX) on the efficacy of gemcitabine (GEM) in a human pancreatic tumor xenograft model. PTX significantly improved the efficacy of GEM, as shown by a 50% reduction in tumor growth rate at 4 weeks of treatment compared with that in animals given GEM alone. The fluorescent drug doxorubicin (DOX) was used to test whether drug delivery was improved by PTX, contributing to the improved efficacy of GEM. PTX given for 2 weeks prior to giving DOX improved drug distribution by 1.8- to 2.2-fold with no changes in vessel density, suggesting that improvement in drug delivery was not related to the vascular mechanism. Instead, collagen I content in tumor stroma was significantly reduced, as was the expression of alpha-smooth muscle actin of cancer-associated fibroblasts and connective tissue growth factor (CTGF) by PTX pretreatment. Overall, our data demonstrated that increased efficacy of GEM by PTX was associated with improved drug delivery to tumor tissue, which may be attributed to decreased expression of CTGF and subsequent reduction in the stromal collagen matrix in the pancreatic ductal adenocarcinoma tumor. These results support the usefulness of PTX in combination with chemotherapy for targeting drug delivery barriers associated with the stromal matrix, which should be further evaluated for clinical development. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/cas.13405 | - |
dc.identifier.bibliographicCitation | CANCER SCIENCE, v.108, no.12, pp 2470 - 2477 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000417079600019 | - |
dc.identifier.scopusid | 2-s2.0-85033213753 | - |
dc.citation.endPage | 2477 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2470 | - |
dc.citation.title | CANCER SCIENCE | - |
dc.citation.volume | 108 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Connective tissue growth factor | - |
dc.subject.keywordAuthor | desmoplasia | - |
dc.subject.keywordAuthor | gemcitabine | - |
dc.subject.keywordAuthor | pancreatic ductal adenocarcinoma | - |
dc.subject.keywordAuthor | pentoxifylline | - |
dc.subject.keywordPlus | TISSUE GROWTH-FACTOR | - |
dc.subject.keywordPlus | DOXORUBICIN DNA-BINDING | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | DUCTAL ADENOCARCINOMA | - |
dc.subject.keywordPlus | CANCER PROGRESSION | - |
dc.subject.keywordPlus | COLLAGEN | - |
dc.subject.keywordPlus | FIBROSIS | - |
dc.subject.keywordPlus | MICROENVIRONMENT | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.